FDA says Lilly weight loss drug shortage is over

FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA says knockoff versions of weight loss drug must come off the market
Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday.
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
FDA declares shortage over for popular weight-loss, diabetes drugs
The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic versions of Mounjaro or Zepbound.
US FDA says Lilly’s weight-loss drug shortage is resolved
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster weight loss and diabetes drugs following a re-evaluation of their supply by the agency.
FDA approves weight loss drug Zepbound for sleep apnea
Popular weight loss drug Zepbound, which is already approved to treat obesity, now becomes the first drug to ever treat sleep apnea, a sleeping disorder that impacts nearly 40 million people.
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
Hosted on MSN2d
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s ...
Becker's Hospital Review2d
FDA: No more need for compounded versions of Mounjaro, Zepbound
The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...
FiercePharma3d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.